Cardio-Oncologie: étude Pilote évaluant la faisabilité, Utilité Concrète, Interdisciplinaire d'Une Unité Spécialisée
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 5,000
- Locations
- 1
- Primary Endpoint
- Incidence of cardio-toxicty
Study Overview
Brief Summary
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias.
CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt.
The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •referred to cardio-oncology
Exclusion Criteria
- •refusal to participate
Outcomes
Primary Outcomes
Incidence of cardio-toxicty
Time Frame: 5 years
Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic
Secondary Outcomes
- Analysis of cardioprotective strategies(5 years)
- Analysis of underlying cardiovacsular profile(5 years)
- Cardiovascular outcomes(10 years)
- Behaviour(5 years)
- Metabolic(5 years)
- Oncology(5 years)
- Any advserse event(5 years)
- Analysis of arrhythmias(5 years)
- Precision medicine(5 years)
- Analysis of cardiotoxicity(5 years)
Investigators
Mariana Mirabel
MD, PhD, Assosiate Professor
European Georges Pompidou Hospital